WO2015122858A1 - Composition contenant des composants synthétiques formée pour supprimer la ribonucléotide réductase - Google Patents

Composition contenant des composants synthétiques formée pour supprimer la ribonucléotide réductase Download PDF

Info

Publication number
WO2015122858A1
WO2015122858A1 PCT/TR2014/000171 TR2014000171W WO2015122858A1 WO 2015122858 A1 WO2015122858 A1 WO 2015122858A1 TR 2014000171 W TR2014000171 W TR 2014000171W WO 2015122858 A1 WO2015122858 A1 WO 2015122858A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzopyrene
buten
hydroxyethyl
bis
ribonucleotide reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2014/000171
Other languages
English (en)
Inventor
Can Alkoçlar ERDAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015122858A1 publication Critical patent/WO2015122858A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to a connposition containing synthetic components formed for suppressing ribonucleotide reductase.
  • Ribonucleotide reductase is an enzyme that catalyzes the reduction of the ribonucleotides in all the existing organisms and the conversion of the same to the deoxyribonucleotides, which are the constituents of DNA. This reaction is also the rate-controlling step in the biosynthesis of DNA.
  • This enzyme having a quite important function, is comprised by two subunits called R1 and R2.
  • the R2 unit via the binuclear Fe (II) center present in its active site, reduces and activates the molecular oxygen, and as a result, a long-lasting tyrosyl radical forms in the R1 subunit.
  • EP1748767B1 entitled “1 -(3- methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane as a potent tyrosinase inhibitor" under the classification "A61 K 31/015" comprises the compound 1 -(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane.
  • Said compound inhibits the activity of an enzyme with a binuclear active site, referred to herein as a binuclear enzyme, and said compound may be administered in an effective amount to an host in need thereof, wherein said compound may be synthesized and/or isolated from one or more plants.
  • binuclear enzymes include, but are not limited to tyrosinase, arginase, urease, cytochrome c oxidase, proton pumping heme-copper oxidase, bifunctional carbon monoxide dehydrogenase/acetyl- coenzyme A synthase, ribonucleotide reductase, metalo-beta-lactamase, H(+)- ATPase and alternative oxidase and bacterial phosphotriesterase.
  • the invention no. ⁇ 170 ⁇ 621 ⁇ 1 entitled "Process for the production of compositions containing ribonucleotides for use as flavoring agents” discloses a process to produce a composition containing 5'-ribonucleotides wherein said process comprises subjecting a microorganism to autolysis under conditions at which a substantial part of the RNA remains in a form degradable into 5'-ribonucleotides and at which a substantial part of the RNA remains associated with the cell wall fraction. Said cell wall fraction is recovered by a solid/liquid separation method and the RNA associated with said cell wall fraction is converted to 5'-ribonucleotides.
  • the invention also discloses the compositions containing 5'-ribonucleotides and the use thereof in the food or feed.
  • EP1480634B1 entitled “Selective androgen receptor modulators (SARMs) for treating benign prostate hyperplasia” provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N- oxide, or any combination thereof as described herein.
  • SARM selective androgen receptor modulator
  • This invention also provides a method of treating a subject suffering from hair loss, comprising the step of administering to the subject a therapeutically effective amount of a 5-a reductase enzyme type 1 and /or type 2 inhibitor, wherein said inhibitor is a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein.
  • SARM selective androgen receptor modulator
  • This invention also provides a method of inhibiting a 5-a reductase type 1 and/or type 2 enzyme, comprising contacting the enzyme with an effective 5-a reductase inhibitory amount of a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, as described herein.
  • SARM selective androgen receptor modulator
  • an object of the invention is to enable the suppression of DNA gyrase.
  • Another object of the invention is to enable the suppression of hemagglutinin esterase. Another object of the invention is to enable the suppression of integrase.
  • the invention is a composition for suppressing ribonucleotide reductase, said composition being obtained by the components selected from the group comprising 3,7-bis(2-hydroxyethyl)3,5,7- trihydroxy-2-(4-metoxyphenyl)-8-(3-methyi-2-buten-1-yl)-4H-1-benzopyrene-4-one, 3,5-bis(2-hydroxyethyl)3,5J-trihydroxy-2-(4-metoxyphenyl)-8-(3-methyl-2-buten-1-yl)- 4H-1-benzopyrene-4-one, 3,7-bis(2-hydroxyethyl)3,5,7-dihydroxy-2-(4- methoxyphenyl)-8-(3-ethyl-2-buten-1-yl)-4H-1 -benzopyrene-4-one that are used individually or in combinations
  • the invention is a composition containing synthetic components formed for 15 suppressing ribonucleotide reductase.
  • the composition according to the invention enables the suppression of DNA gyrase, DNA ligase, ribonucleotide reductase, reverse transcriptase, DNA polymerase, hemagglutinin esterase, integrase and DNA methyltransferase.
  • composition according to the invention contains 3,7-bis(2-hydroxyethyl)3,5,7- trihydroxy-2-(4-metoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyrene-4-one, 3,5-bis(2-hydroxyethyl)3,5,7-trihydroxy-2-(4-metoxyphenyl)-8-(3-methyl-2-buten-1 -yl)- 4H-1 -benzopyrene-4-one, 3,7-bis(2-hydroxyethyl)3,5,7-dihydroxy-2-(4- methoxyphenyl)-8-(3-ethyl-2-buten-1 -yl)-4H-1 -benzopyrene-4-one.
  • composition is obtained by a mixture of the aforesaid components according to the following ratios by weight:
  • composition 50-5% 3,7-bis(2-hydroxyethyl)3,5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-ethyl-2- buten-1-yl)-4H-1 -benzopyrene-4-one.
  • the composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.
  • Said invention also encompasses the use of said composition for suppressing ribonucleotide reductase and the manufacture thereof for this purpose.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition formée pour supprimer la ribonucléotide réductase.
PCT/TR2014/000171 2014-02-15 2014-05-13 Composition contenant des composants synthétiques formée pour supprimer la ribonucléotide réductase Ceased WO2015122858A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2014/01788 2014-02-15
TR201401788 2014-02-15

Publications (1)

Publication Number Publication Date
WO2015122858A1 true WO2015122858A1 (fr) 2015-08-20

Family

ID=51136754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2014/000171 Ceased WO2015122858A1 (fr) 2014-02-15 2014-05-13 Composition contenant des composants synthétiques formée pour supprimer la ribonucléotide réductase

Country Status (1)

Country Link
WO (1) WO2015122858A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012682A2 (fr) * 2002-08-02 2004-02-12 The Ohio State University Research Foundation 3-aryl-4h-1-benzopyran-4-ones heterosubstituees en position 2 en tant que nouvelles substances de traitement du cancer du sein
KR20100026113A (ko) * 2008-08-29 2010-03-10 건국대학교 산학협력단 5-하이드록시-2-(3-하이드록시페닐)-6,7,3'-메톡시-4에이치-1-벤조피란-4-온의 항암제로서의 용도
EP1480634B1 (fr) 2002-02-07 2011-08-03 University of Tennessee Research Foundation Modulateurs sélectifs de récepteur androgène (SARMs) pour le traitement de l'hypertrophie bénigne de la prostate.
EP1748767B1 (fr) 2004-05-28 2011-12-28 Unigen, Inc. 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane comme inhibiteur puissant de la tyrosinase
EP1701621B1 (fr) 2004-01-09 2013-08-14 DSM IP Assets B.V. Procédé de préparation de compositions renfermant des ribonucleotides pour l'usage comme agents aromatisants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480634B1 (fr) 2002-02-07 2011-08-03 University of Tennessee Research Foundation Modulateurs sélectifs de récepteur androgène (SARMs) pour le traitement de l'hypertrophie bénigne de la prostate.
WO2004012682A2 (fr) * 2002-08-02 2004-02-12 The Ohio State University Research Foundation 3-aryl-4h-1-benzopyran-4-ones heterosubstituees en position 2 en tant que nouvelles substances de traitement du cancer du sein
EP1701621B1 (fr) 2004-01-09 2013-08-14 DSM IP Assets B.V. Procédé de préparation de compositions renfermant des ribonucleotides pour l'usage comme agents aromatisants
EP1748767B1 (fr) 2004-05-28 2011-12-28 Unigen, Inc. 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane comme inhibiteur puissant de la tyrosinase
KR20100026113A (ko) * 2008-08-29 2010-03-10 건국대학교 산학협력단 5-하이드록시-2-(3-하이드록시페닐)-6,7,3'-메톡시-4에이치-1-벤조피란-4-온의 항암제로서의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 201048, Derwent World Patents Index; AN 2010-D06268, XP002730591 *
TOBIAS CHAPMAN: "Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization", FRONTIERS IN ONCOLOGY, vol. 1, 1 January 2012 (2012-01-01), XP055143438, ISSN: 2234-943X, DOI: 10.3389/fonc.2011.00056 *

Similar Documents

Publication Publication Date Title
Feng et al. Roles of Mycobacterium smegmatis D-alanine: D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine
Carell et al. Non‐canonical bases in the genome: the regulatory information layer in DNA
Chang et al. Biosynthetic pathway and gene cluster analysis of Curacin A, an Antitubulin natural product from the tropical Marine Cyanobacterium Lyngbya m ajuscula
JP2019070653A (ja) ヒトｅｚｈ２の阻害剤、およびその使用方法
Jun et al. Synergistic cooperation between phorbol ester and IFN-gamma for induction of nitric oxide synthesis in murine peritoneal macrophages.
Walsh et al. Aminobenzoates as building blocks for natural product assembly lines
Zhu et al. Insights into caerulomycin A biosynthesis: a two-component monooxygenase CrmH-catalyzed oxime formation
Liebhold et al. Regiospecific benzylation of tryptophan and derivatives catalyzed by a fungal dimethylallyl transferase
JP2013540767A (ja) 免疫不全ウイルス転写を調節するための組成物および方法
US20220226269A1 (en) Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
JP6066439B2 (ja) リベロマイシンａまたはその合成中間体の製造法、スピロケタール環含有化合物の製造方法、並びに新規抗癌剤、抗真菌剤および骨疾患治療剤
Li et al. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non‐small cell lung cancer cells
Machado Motta Kinetoplast as a potential chemotherapeutic target of trypanosomatids
Mizushina et al. Anti-cancer gallotannin penta-O-galloyl-beta-D-glucose is a nanomolar inhibitor of select mammalian DNA polymerases
WO2015122858A1 (fr) Composition contenant des composants synthétiques formée pour supprimer la ribonucléotide réductase
Kujundžić et al. The role of tryptophan metabolism in iNOS transcription and nitric oxide production by chicken macrophage cells upon treatment with interferon gamma
Bakhanashvili et al. Excision of nucleoside analogs in mitochondria by p53 protein
FR2600256A1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
Venturini et al. Selective inhibition of nitric oxide synthase type I by clonidine, an anti-hypertensive drug
Furda The role of mtDNA damage in mitochondrial dysfunction
EP1069911A1 (fr) Nitroreductase nouvelle et usages therapeutiques associes
von Wartburg et al. Enzymes of biogenic aldehyde metabolism
US12428663B2 (en) Identification of DNA polymerase theta inactivation mechanism
Brown et al. A nuclear 3′–5′ exonuclease proofreads for the exonuclease-deficient DNA polymerase α
Kanamitsu et al. Early steps in the DNA base excision repair pathway of a fission yeast Schizosaccharomyces pombe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14736484

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 20.12.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14736484

Country of ref document: EP

Kind code of ref document: A1